Fluidigm Co. (NASDAQ:FLDM) Shares Sold by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. decreased its holdings in shares of Fluidigm Co. (NASDAQ:FLDM) by 29.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,000 shares of the medical research company’s stock after selling 60,000 shares during the period. Hussman Strategic Advisors Inc.’s holdings in Fluidigm were worth $651,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in FLDM. AdvisorNet Financial Inc acquired a new stake in shares of Fluidigm in the 4th quarter worth approximately $39,000. International Assets Investment Management LLC purchased a new stake in Fluidigm in the 4th quarter valued at approximately $42,000. MTM Investment Management LLC purchased a new stake in Fluidigm in the 1st quarter valued at approximately $45,000. Victory Capital Management Inc. purchased a new stake in Fluidigm in the 4th quarter valued at approximately $64,000. Finally, Metropolitan Life Insurance Co NY purchased a new stake in Fluidigm in the 1st quarter valued at approximately $151,000. Institutional investors own 88.30% of the company’s stock.

FLDM has been the topic of a number of recent research reports. Zacks Investment Research lowered Fluidigm from a “hold” rating to a “sell” rating in a research note on Thursday, February 11th. Piper Sandler reduced their target price on Fluidigm from $15.00 to $8.00 in a research note on Thursday, February 11th.

Shares of Fluidigm stock opened at $5.49 on Wednesday. Fluidigm Co. has a fifty-two week low of $3.33 and a fifty-two week high of $12.45. The firm has a market cap of $411.55 million, a PE ratio of -8.19 and a beta of 1.87. The business’s fifty day moving average is $4.69 and its two-hundred day moving average is $5.65. The company has a quick ratio of 2.41, a current ratio of 2.87 and a debt-to-equity ratio of 0.36.

Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings results on Thursday, May 6th. The medical research company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.19). Fluidigm had a negative return on equity of 19.25% and a negative net margin of 37.85%. Equities research analysts anticipate that Fluidigm Co. will post -0.41 EPS for the current year.

Fluidigm Profile

Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology.

Featured Article: How are capital gains distributions different for tax-deferred account?

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.